FDA Extends INCY's Application for Opzelura Label Expansion
FDA Review Extension: Incyte's supplemental new drug application for ruxolitinib cream, aimed at treating mild to moderate atopic dermatitis in children aged 2-11, has had its review period extended by three months to September 19, 2025, due to the need for additional data review.
Market Performance and Drug Portfolio: Despite a slight decline in shares year-to-date, Incyte is expanding its portfolio beyond its lead drug Jakafi, with recent approvals of other drugs like Monjuvi and Zynyz contributing to growth, although competition and patent expiration concerns for Jakafi remain significant challenges.
Trade with 70% Backtested Accuracy
Analyst Views on IMCR
About IMCR
About the author
Immunocore (IMCR) Q4 2025 Earnings Call Transcript
Immunocore Q4 Earnings Report Analysis
- Disappointing Earnings: Immunocore reported a Q4 GAAP EPS of -$0.60, missing expectations by $0.42, indicating challenges in profitability that may affect investor confidence.
- Lackluster Revenue Growth: Although revenue increased by 24.3% year-over-year to $104.48 million, it fell short of expectations by $3.29 million, reflecting intensified market competition and a need for strategic adjustments in sales.
- Strong Cash Reserves: As of December 31, 2025, Immunocore held $864.2 million in cash, cash equivalents, and marketable securities, ensuring ample funding for future R&D and operations, thereby enhancing financial stability.
- Uncertain Market Outlook: Immunocore's presentation at the J.P. Morgan Healthcare Conference garnered attention, yet the current financial data may lead to diminished investor confidence regarding its future growth prospects.
Immunocore Set to Announce Q4 Earnings on February 25
- Earnings Announcement: Immunocore (IMCR) is scheduled to release its Q4 earnings on February 25 before the market opens, with investors keenly awaiting the results to gauge the company's growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$0.20, reflecting a 57.4% year-over-year increase, indicating significant improvement in profitability despite remaining in negative territory.
- Revenue Expectations: The consensus revenue estimate is $107.77 million, representing a 28.2% year-over-year growth, highlighting a positive trend in market demand and product sales for Immunocore.
- Estimate Revisions: Over the past three months, EPS estimates have seen no upward revisions and two downward adjustments, while revenue estimates experienced one upward revision and one downward adjustment, indicating analyst divergence regarding the company's financial outlook.
Immunocore Announces R&D Leadership Changes
- Executive Departure: Immunocore announced that Executive Vice President of R&D David Berman will leave the company on February 27, 2026, to take a role at another biotech firm, indicating a significant leadership transition for the company.
- Internal Promotions: The company is promoting current Chief Medical Officer Mohammed Dar and Head of Regulatory Sciences Mark Moyer to Executive Vice President roles, with expanded responsibilities for clinical development and regulatory strategies, aiming to enhance R&D efficiency by leveraging the existing leadership team.
- R&D Achievements: Dar has led clinical development since 2019, successfully advancing KIMMTRAK to regulatory approval, which is now approved in 39 countries, showcasing the company's strong capabilities in oncology immunotherapy.
- Strategic Commitment: CEO Bahija Jallal expressed confidence in the R&D team despite the executive changes, committing to continue advancing clinical programs to meet patient needs for transformative therapies.
Immunocore to Showcase at Upcoming Investor Events
Company Overview: Immunocore Holdings plc is a biotechnology company focused on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, utilizing its ImmTAX platform for TCR bispecific immunotherapies.
Upcoming Conferences: The company will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference on November 11, 2025, and the Jefferies London Healthcare Conference on November 19, 2025, with live webcasts available on their website.
Product Highlight: Immunocore's leading oncology therapy, KIMMTRAK, is approved for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in several countries, including the US and EU.
Contact Information: For inquiries, Immunocore provides contact details for communications and investor relations, including email addresses and phone numbers.
HC Wainwright & Co. Affirms Buy Rating for Immunocore Holdings, Keeps $100 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.
Immunocore (IMCR) Q4 2025 Earnings Call Transcript
Immunocore Q4 Earnings Report Analysis
- Disappointing Earnings: Immunocore reported a Q4 GAAP EPS of -$0.60, missing expectations by $0.42, indicating challenges in profitability that may affect investor confidence.
- Lackluster Revenue Growth: Although revenue increased by 24.3% year-over-year to $104.48 million, it fell short of expectations by $3.29 million, reflecting intensified market competition and a need for strategic adjustments in sales.
- Strong Cash Reserves: As of December 31, 2025, Immunocore held $864.2 million in cash, cash equivalents, and marketable securities, ensuring ample funding for future R&D and operations, thereby enhancing financial stability.
- Uncertain Market Outlook: Immunocore's presentation at the J.P. Morgan Healthcare Conference garnered attention, yet the current financial data may lead to diminished investor confidence regarding its future growth prospects.
Immunocore Set to Announce Q4 Earnings on February 25
- Earnings Announcement: Immunocore (IMCR) is scheduled to release its Q4 earnings on February 25 before the market opens, with investors keenly awaiting the results to gauge the company's growth potential.
- Earnings Expectations: The consensus EPS estimate stands at -$0.20, reflecting a 57.4% year-over-year increase, indicating significant improvement in profitability despite remaining in negative territory.
- Revenue Expectations: The consensus revenue estimate is $107.77 million, representing a 28.2% year-over-year growth, highlighting a positive trend in market demand and product sales for Immunocore.
- Estimate Revisions: Over the past three months, EPS estimates have seen no upward revisions and two downward adjustments, while revenue estimates experienced one upward revision and one downward adjustment, indicating analyst divergence regarding the company's financial outlook.
Immunocore Announces R&D Leadership Changes
- Executive Departure: Immunocore announced that Executive Vice President of R&D David Berman will leave the company on February 27, 2026, to take a role at another biotech firm, indicating a significant leadership transition for the company.
- Internal Promotions: The company is promoting current Chief Medical Officer Mohammed Dar and Head of Regulatory Sciences Mark Moyer to Executive Vice President roles, with expanded responsibilities for clinical development and regulatory strategies, aiming to enhance R&D efficiency by leveraging the existing leadership team.
- R&D Achievements: Dar has led clinical development since 2019, successfully advancing KIMMTRAK to regulatory approval, which is now approved in 39 countries, showcasing the company's strong capabilities in oncology immunotherapy.
- Strategic Commitment: CEO Bahija Jallal expressed confidence in the R&D team despite the executive changes, committing to continue advancing clinical programs to meet patient needs for transformative therapies.
Immunocore to Showcase at Upcoming Investor Events
Company Overview: Immunocore Holdings plc is a biotechnology company focused on developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases, utilizing its ImmTAX platform for TCR bispecific immunotherapies.
Upcoming Conferences: The company will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference on November 11, 2025, and the Jefferies London Healthcare Conference on November 19, 2025, with live webcasts available on their website.
Product Highlight: Immunocore's leading oncology therapy, KIMMTRAK, is approved for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in several countries, including the US and EU.
Contact Information: For inquiries, Immunocore provides contact details for communications and investor relations, including email addresses and phone numbers.
HC Wainwright & Co. Affirms Buy Rating for Immunocore Holdings, Keeps $100 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.
